MonumenTAL-6 trial strengthens Johnson & Johnson’s dual-target multiple myeloma strategy
Johnson & Johnson’s Tecvayli-Talvey regimen cut progression risk by 89% in MonumenTAL-6. See what the topline data still must prove.
Pharma & Biotech
Medical Devices & Diagnostics
Momentis Surgical Anovo FDA clearance expands robotic surgery to multiport procedures
Momentis Surgical wins FDA clearance for Anovo multiport surgery, widening its robotic platform while adoption and evidence remain key.
Medical Devices & Diagnostics
Johnson & Johnson has entered soft-tissue robotics, but can Ottava loosen da Vinci’s grip?
Johnson & Johnson can launch its table-integrated Ottava surgical robot in the United States, opening a new competitive front against Intuitive Surgical and Medtronic.
Medical Devices & Diagnostics
Johnson & Johnson wins FDA approval for dual-energy Thermocool Smarttouch SF ablation platform
Johnson & Johnson has received U.S. Food and Drug Administration approval for the Dual Energy Thermocool Smarttouch SF Platform, an integrated cardiac ablation system that allows electrophysiologists to deliver both radiofrequency and pulsed field energy through a single catheter. The approval places the Johnson & Johnson MedTech electrophysiology business into a more direct U.S. rollout
Medical Devices & Diagnostics
Johnson & Johnson has a new dual-energy ablation platform, but will hospitals adopt it?
Find out how Johnson & Johnson’s dual-energy ablation system could reshape cardiac arrhythmia procedures.
Pharma & Biotech
Can IMAAVY’s sustained control data reshape earlier treatment of generalized myasthenia gravis?
Discover what Johnson & Johnson’s new IMAAVY data mean for earlier gMG treatment, sustained control, safety and FcRn competition.
Medical Devices & Diagnostics
How Johnson & Johnson’s dual-energy THERMOCOOL platform could reshape European atrial fibrillation ablation
The Dual Energy THERMOCOOL SMARTTOUCH SF Platform gives electrophysiologists pulsed field and radiofrequency ablation through one catheter, expanding procedural flexibility while raising new questions about evidence, efficiency and adoption.
Pharma & Biotech
Johnson & Johnson strengthens nipocalimab’s FDA case with rapid hemoglobin improvement
The ENERGY trial strengthens the regulatory case for nipocalimab in warm autoimmune hemolytic anemia, but modest response rates and long-term IgG suppression remain important questions.
Features & Analysis
Can Sanofi’s CirCLIQ strategy change how anti-CD38 therapies reach patients?
Discover how wearable injectors could reshape multiple myeloma treatment, clinic capacity and the competitive battle between Sarclisa and daratumumab.
Pharma & Biotech
Johnson & Johnson’s IMAAVY data sharpen the FcRn strategy beyond myasthenia gravis
Find out how Johnson & Johnson’s IMAAVY data could reshape treatment strategy in warm autoimmune hemolytic anemia.